# CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Source: https://onco.cc/trials/nct06037980/  
OnCo record `nct06037980` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of gemcitabine, cisplatin, capecitabine and paclitaxel in gallbladder cancer and other biliary tract cancers, run by Gruppo Oncologico del Nord-Ovest, now recruiting.

## Summary

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence is a phase 2/3, randomised interventional study registered as NCT06037980 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 300 participants, started 2023-11-07 and due to reach its primary completion in 2028-12. Interventions recorded: Gemcitabine, Nab paclitaxel, Cisplatin, Curative Surgery, Capecitabine. Conditions listed: Biliary Tract Cancer, Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "3. Histologically or cytologically confirmed non metastatic resectable carcinoma of biliary tract (BTC), including gallbladder carcinoma (GBC), intrahepatic, periperihilar or distal Cholangiocarcinoma (CCA). Mixed tumor ". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PURITY
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06037980
- Phase: 2/3
- Setting: A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06037980: https://clinicaltrials.gov/study/NCT06037980

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/), [Hepatectomy (liver resection)](https://onco.cc/terms/hepatectomy/)

---
JSON: https://onco.cc/api/v1/entities/nct06037980.json